Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II biomarker-based equivalence study of abiraterone acetate tablet (II) vs Zytiga in metastatic castration-resistant prostate cancer
CTR20242370Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abiraterone in prostate cancer (PCa), sponsored by Nanjing Shunxin Pharmaceutical. Started Sep 2024; status: active.
02
Drugs
abiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20242370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242370.